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Simultaneous control of blood glucose and other risk factors such as hypertension and dyslipidaemia is essential for reducing the risk of
complications associated with type 2 diabetes mellitus (T2DM). As relatively few patients with T2DM have their risk factors managed to within
the limits recommended by the American Diabetes Association, American College of Endocrinology or National Cholesterol Education Program
Adult Treatment Panel III guidelines, treatment that can simultaneously control more than one risk factor is of therapeutic beneﬁt. Clinical
studies have shown that bile acid sequestrants have glucose-lowering effects in addition to their low-density lipoprotein cholesterol-lowering
effects in patients with T2DM. The bile acid sequestrant colesevelam hydrochloride is approved as an adjunct to antidiabetes therapy for
improving glycaemic control in adults with T2DM. This review examines data from three phase III clinical trials that evaluated the glucose- and
lipid-lowering effects of colesevelam when added to the existing antidiabetes treatment regimen of patients with T2DM.
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Introduction
Heart disease and stroke are the leading cause of mortality in
patients with diabetes, accounting for approximately 65% of
deaths in this group [1,2]. The hyperglycaemia that accompa-
niesuncontrolledtype2diabetesmellitus(T2DM)isoftenasso-
ciatedwith hypertension and dyslipidaemia, which combine to
result in signiﬁcant microvascular (retinopathy, nephropathy
and neuropathy) and macrovascular [cardiovascular disease
(CVD), stroke and peripheral arterial disease] complications
thatare the hallmark of T2DM [2–4]. Simultaneous controlof
hyperglycaemia, hypertension and dyslipidaemia is, therefore,
essential forreducing the risk of complicationsin patients with
T2DM.
Epidemiological evidence suggests that the presence
of microvascular complications [predicted by glycosylated
haemoglobin(HbA1c)levels]mayincreasetheriskofdevelop-
ingmacrovascularcomplicationsinpatientswithT2DM[5–7].
Although glycaemic control has been shown to have a clear
role in reducing the risk of microvascular complications in
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patients with T2DM, the effect of glycaemic control on
macrovascular disease risk is still under investigation [8,9].
Evidence from recent clinical trials suggests that intensive
glucose-lowering therapy [treating to HbA1c target levels
<6.0% (42.0 mmol/mol)] is not correlated with a reduction
in CVD events [10,11]. Intervention to manage multiple risk
factors(hyperglycaemia,hypertensionanddyslipidaemia)con-
currently in patients with T2DM can reduce the risk of CVD
by approximately 50% [12]. However, as highlighted by data
from the National Health and Nutrition Examination Survey
evaluating trends between 1999–2000 and 2003–2004,there is
still room for improvement in attaining simultaneous control
of hyperglycaemia, hypertension and dyslipidaemia [13–15].
Speciﬁcally, while the proportion of patients achieving gly-
caemic target levels [HbA1c <7.0% (53 mmol/mol)], blood
pressure(<130/80mmHg),andtotalcholesterol[<200 mg/dl
(<5.2 mmol/l)] increased from 35.8 to 57.1%, 35.7 to 48.3%
and 48.8 to 50.4% respectively, the proportion of patients
achieving all three treatment goals remained low, increasing
from 7.5 to 13.2% [15]. These data indicate that there is still
a clear need for intensive treatment to improve cardiovascular
risk factor management in most patients with T2DM.
Bile acid sequestrants are well-established therapies for the
treatmentofhyperlipidaemia,andtherapywithcholestyramine
has been shown to contribute to reductions in both the
progression of coronary heart disease and in the risk of
CVD events [16,17]. Compared with the ﬁrst-generation bileDIABETES, OBESITY AND METABOLISM review article
acid sequestrants (cholestyramine and colestipol), the second-
generation bile acid sequestrant colesevelam hydrochloride
(HCl) has a greater binding capacity for bile acids [18].
Clinical studies have shown that colesevelam monotherapy
can lower low-density lipoprotein cholesterol (LDL-C) levels
by 15–19% [19–21]. Furthermore, colesevelam can be safely
combined with existing statin therapy in patients who
would beneﬁt from additional LDL-C lowering. Colesevelam,
in combination with statin therapy, can result in LDL-C
reductions of 42% (with simvastatin 10 mg) to 48% (with
atorvastatin 10 mg) [22,23]. In 2000, the US Food and Drug
Administration (FDA) approved the use of colesevelam for the
treatment of hyperlipidaemia.
Clinical evidence has suggested that bile acid sequestrants
could also improve glycaemic control in patients with
T2DM [24–28],andthisevidencewasthebasisfortheapproval
ofcolesevelambytheUSFDAin2008asanadjuncttherapyfor
glycaemic control in adults with T2DM. This review examines
the clinical data from these recent trials with colesevelam in
patients with T2DM.
Clinical Trials with Colesevelam HCl in
Patients with T2DM
The addition of colesevelam to established antidiabetes
monotherapy or combination therapy with metformin,
sulfonylureas or insulin in patients with T2DM was evaluated
in three randomized, double-blind, placebo-controlledclinical
trials [26–28]. The trials enrolled a total of 1064 patients
with T2DM with inadequate glycaemic control [HbA1c of
7.5–9.5% (58.5–80.3 mmol/mol), inclusive] on their current
antidiabetes treatment regimen (table 1) [26–28]. Baseline
glucose and lipid characteristics were similar among patients
in the three trials, with baseline HbA1c levels ranging from
8.1 to 8.3% (65.0–67.2 mmol/mol) and baseline LDL-C levels
ranging from 99.0 to 106.0 mg/dl (2.6 to 2.8 mmol/l) (table 1).
The three populations were similar in demographics; mean
age (approximately 56 years); male gender (51.0–56.0%);
and race: Caucasian (56.0–64.0%), Black (10.0–19.0%) and
Latino (16.0–29.0%). Compliance with study medication
across the three trials ranged from 92.7 to 93.3% with
colesevelam and 90.8 to 94.5% with placebo [26–28]. In
addition, a similar proportion of patients were on statin
therapyatbaseline[137/316;43.0%(metformintrial),187/461;
40.6% (sulfonylurea trial), and 164/287; 57.1% (insulin
trial)] [26–28].
Trial 1: Colesevelam HCl Added to Metformin-Based
Therapy [26]
GlucoseEffects. Whenaddedtoestablishedmetformintherapy,
colesevelam resulted in further reductions in HbA1c at
week 6 [−0.49 vs. −0.03% for placebo (−28.9 mmol/mol vs.
−23.8 mmol/mol); p < 0.001]. By the end of the trial at week
26, the mean treatment difference (placebo-corrected change
from baseline) in HbA1c was −0.54% (−29.4 mmol/mol;
p < 0.001)(ﬁgure 1A).Inaddition,colesevelamwasassociated
with a signiﬁcant reduction in fasting plasma glucose at
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Figure 1. Mean change from baseline to endpoint LOCF in (A) HbA1c and (B) FPG with addition of colesevelam hydrochloride compared with placebo
to ongoing metformin, sulfonylurea or insulin antidiabetes therapies in patients with T2DM. Endpoint was 26 weeks in the metformin and sulfonylurea
trials, and 16 weeks in the insulin trial. Numbers above the bracketed pairs of bars are the mean treatment difference from baseline ± s.e. N is the number
of patients with values at both baseline and endpoint. For HbA1c conversion from % to mmol/mol (%HbA1c—2.15*10.929); for FPG conversion from
mg/dl to mmol/l, multiply by 0.0555. FPG, fasting plasma glucose; HbA1c, glycosylated haemoglobin; HCl, hydrochloride; LOCF, last observation carried
forward; T2DM, type 2 diabetes mellitus.
week 26 (treatment difference: −13.9m g / d l[ −0.8 mmol/l];
p = 0.014) (ﬁgure 1B). As a result, a signiﬁcantly greater
proportion of colesevelam-treated patients achieved the
prespeciﬁed glycaemic goals [reduction in HbA1c ≥0.7%
(≥15.8 mmol/mol) and/or fasting plasma glucose ≥30 mg/dl
(1.7 mmol/l) at week 26] compared with placebo-treated
patients (47.7 vs. 35.5%; p = 0.033).
A prespeciﬁed subgroup analysis investigated the effects
of colesevelam when added to metformin monotherapy or
metformin combination antidiabetes therapy. At week 26,
the addition of colesevelam to metformin monotherapy
resulted in a mean treatment difference in HbA1c of
−0.47% (−28.6 mmol/mol; p = 0.002) while the addition
of colesevelam to metformin in combination with other
antidiabetes therapy resulted in a mean treatment difference
in HbA1c of −0.62% (−30.3 mmol/mol; p < 0.001) (table 2).
In this trial, the most common antidiabetes medications used
in combination with metformin were sulfonylureas (69.4%)
and thiazolidinediones (36.3%). These results suggest that
colesevelam is versatile as an adjunctive treatment for T2DM,
as it can be added early (to metformin monotherapy) or later
intreatment(toantidiabetescombinationtherapy)toimprove
glycaemic control.
LipidEffects. Theadditionofcolesevelamtometformintherapy
resulted in a signiﬁcant reduction in LDL-C of approximately
16% (p < 0.001) at week 26 (ﬁgure 2; table 3). In addition,
there were signiﬁcant reductions in total cholesterol and non-
high-density lipoprotein cholesterol (non-HDL-C) following
treatmentwithcolesevelamcomparedwithplacebo(treatment
difference:−7.2and−10.3%respectively;p < 0.001forboth).
The levels of HDL-C increased from baseline with both
colesevelam and placebo by week 26, although the mean
treatment difference between the groups was not signiﬁcant
(ﬁgure 2; table 3).
Theeffectofcolesevelamonnon-HDL-Clevelsisinteresting
given that non-HDL-C is considered a secondary target of
lipid-loweringtherapyinpatientswithT2DMwithtriglyceride
levels ≥200 mg/dl (≥2.3 mmol/l) [29]. Non-HDL-Clevels can
provide a single, reliable index of atherogenic apolipoprotein
(apo) B-containing lipoproteins, and guidelines from the third
National Cholesterol Education Program Adult Treatment
Panel recommend that non-HDL-C levels be lowered to
<130 mg/dl (<3.4 mmol/l) to aid in the reduction of CVD
events in patients with T2DM at highest cardiovascular risk,
withanoptionalgoalof<100 mg/dl(<2.6 mmol/l)inpatients
with high triglycerides [29–31].
There were improvements with colesevelam in the lipopro-
tein ratios that are most predictive of CVD risk [29,32]. These
included reductions in the ratios of total cholesterol/HDL-
C, LDL-C/HDL-C, non-HDL-C/HDL-C and apoB/apoA-I (p
≤ 0.002 vs. placebo for all). The clinical effect of these reduc-
tions was not examined in these trials.
Patients treated with colesevelam exhibited a moderate,
but non-signiﬁcant increase in triglyceride levels compared
withplacebo(treatmentdifference:4.7%;p = 0.221)(ﬁgure 2;
table 3). According to the standards of care developed by
the American Diabetes Association, patients with T2DM with
unacceptable triglyceride levels [≥150 mg/dl (≥1.7 mmol/l)]
may require additional therapy to manage their dyslipi-
daemia [8].Interestingly,asimilarproportionofpatientsinthe
colesevelam and placebo treatment groups who had a baseline
triglyceride level <150 mg/dl (<1.7 mmol/l) had an increase
in their triglyceride levels to ≥150 mg/dl (≥1.7 mmol/l) at
any time during follow-up [12.1% (colesevelam group) vs.
12.5% (placebo group)]. In addition, 8.7% of patients in
the colesevelam group and 5.9% of patients in the placebo
group who had a baseline triglyceride level of ≥150 mg/dl
(≥1.7 mmol/l) experienced a reduction in their triglyceride
levelsto<150 mg/dl(<1.7 mmol/l)afterreceivingstudymed-
ication.Similarresultswereseenintheinsulinandsulfonylurea
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trials with regard to triglyceride levels. Patients treated with
colesevelam had a signiﬁcant reduction in high-sensitivity C-
reactiveprotein(hsCRP)levelscomparedwithplacebo(median
treatment difference: −0.4m g / l[ −14.4%]; p = 0.02) at week
26 (ﬁgure 3) [26].
Trial 2: Colesevelam HCl Added to Sulfonylurea-Based
Therapy [27]
Glucose Effects. The addition of colesevelam to established
sulfonylurea monotherapy or combination therapy resulted
in a further reduction in HbA1c, with an overall mean
treatment difference of −0.54% (−29.4 mmol/mol; p <
0.001) after 26 weeks (ﬁgure 1A). A signiﬁcant reduction
in HbA1c occurred when colesevelam was added to either
sulfonylurea monotherapy (treatment difference: −0.79%
[−32.1 mmol/mol]; p < 0.001) or sulfonylurea combination
therapy [−0.42% (−28.1 mmol/mol); p < 0.001] (table 2).
Theadditionofcolesevelamtoexistingantidiabetesmonother-
apy or combination treatment suggests the potential beneﬁt
of its use in patients with early and established T2DM.
Colesevelam also resulted in a signiﬁcant mean treatment
difference in fasting plasma glucose at week 26 (−13.5m g / d l
[−0.75 mmol/l]; p = 0.009) (ﬁgure 1B). The percentage of
patients who achieved either a reduction in HbA1c ≥0.7%
[≥15.8 mmol/mol] and/or fasting plasma glucose ≥30 mg/dl
[1.7 mmol/l] at week 26 was greater in the colesevelam group
compared with the placebo group (47.5 vs. 32.1% respectively;
p = 0.001).
Lipid Effects. Colesevelam resulted in a signiﬁcant mean
treatment difference from baseline in LDL-C at week 26
(−16.7%; p < 0.001) (ﬁgure 2; table 3), as well as signiﬁcant
reductions in total cholesterol and non-HDL-C by the end of
the trial (treatment difference: −5.0a n d−6.7% respectively;
p < 0.001 for both). While HDL-C levels increased from
baseline with both colesevelam and placebo treatment, the
changes were not signiﬁcant. The total cholesterol/HDL-
C, LDL-C/HDL-C, non-HDL-C/HDL-C and apoB/apoA-I
ratios were signiﬁcantly improved in the colesevelam group
(p ≤ 0.003 vs. placebo). Compared with placebo, patients
who received colesevelam had increased triglyceride levels
[treatment difference: 17.7%; p < 0.001) (ﬁgure 2) and a
non-signiﬁcant reduction in hsCRP levels (median treatment
difference: −0.4m g / l( −11.2%); p = 0.06] from baseline to
week 26 (ﬁgure 3) [27,33].
Trial 3: Colesevelam HCl Added to Insulin-Based
Therapy [28]
Glucose Effects. The addition of colesevelam to stable insulin
only therapy or insulin therapy in combination with oral
antidiabetes agents resulted in an additional reduction in
HbA1c [treatment difference: −0.50% (−29.0 mmol/mol);
p < 0.001] (ﬁgure 1A) after 16 weeks. This reduction in
HbA1c with colesevelam was apparent and signiﬁcant from
the ﬁrst assessment at week 4 [−0.32 vs. −0.02% for placebo
(−27.0v s . −23.7 mmol/mol); p < 0.001]. In addition, the
reduction in HbA1c with colesevelam was signiﬁcant whether
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Figure 2. Mean change from baseline to endpoint in lipid parameters with addition of colesevelam HCl compared with placebo to ongoing metformin,
sulfonylurea or insulin antidiabetes therapies in patients with T2DM. Mean values are reported unless otherwise indicated. Apo, apolipoprotein; HCl,
hydrochloride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LOCF, last observation carried forward; LS,
least-squares; TC, total cholesterol; T2DM, type 2 diabetes mellitus; TG, triglycerides.
colesevelam was added to ongoing insulin only therapy
[−0.59% (−29.9 mmol/mol); p < 0.001] or insulin therapy
in combination with oral antidiabetes agent(s) [−0.44%
(−28.3 mmol/mol); p < 0.001] (table 2). Although fasting
plasma glucose was reduced from baseline with colesevelam,
the mean treatment difference was not signiﬁcant at week 16
[−14.6m g / d l( −0.8 mmol/l); p = 0.08] (ﬁgure 1B). Overall,
a greater proportion of patients in the colesevelam group
compared with the placebo group achieved either a reduction
in HbA1c ≥0.7% (≥15.8 mmol/mol) and/or fasting plasma
glucose ≥30 mg/dl (1.7 mmol/l) at week 16 (48.6 vs. 31.6%
respectively; p = 0.004).
Lipid Effects. At week 16, colesevelam signiﬁcantly reduced
LDL-C levels as evidenced by a mean treatment difference of
−12.8% (p < 0.001). Although the addition of colesevelam
to insulin therapy also resulted in reductions from baseline
in total cholesterol, non-HDL-C, and HDL-C at week 16
(ﬁgure 2; table 3), these reductions were not signiﬁcant
compared with placebo. While improvement was seen in
the lipoprotein ratios conferring greatest cardiovascular risk
in the colesevelam group, the difference between groups was
signiﬁcant only for the ratios of LDL-C/HDL-C (p < 0.001)
and apoB/apoA-I (p = 0.004). In addition, patients treated
with colesevelam exhibited a signiﬁcant increase in triglyceride
levelscomparedwithplacebo(treatmentdifference:21.5%;p <
0.001)(ﬁgure 2;table 3).Therewasanon-signiﬁcantreduction
in hsCRP levels at week 16 last observation carried forward
with colesevelam compared with placebo [median treatment
difference:−0.4m g / l( −12.2%);p > 0.05](ﬁgure 3),however,
the reduction in hsCRP levels was signiﬁcant in the cohort of
patientswhocompletedthestudyatweek16[mediantreatment
difference: −0.6m g / l( −18.6%); p ≤ 0.01] [28,33].
Colesevelam HCl Provides Dual Lipid- and
Glucose-Lowering Beneﬁts in Patients with
T2DM
The addition of colesevelam resulted in a consistent
reduction in HbA1c [ranging from 0.50–0.54% (−29.0
to −29.4 mmol/mol)] across all three trials, regardless of
the background antidiabetes medication used, that was
accompanied by reductions in fasting plasma glucose.
Furthermore, colesevelam treatment resulted in a greater
percentage of patients achieving either a reduction in HbA1c
≥0.7% (≥15.8 mmol/mol) and/or fasting plasma glucose
≥30 mg/dl (1.7 mmol/l) at study endpoint compared with
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Table 3. Changefrom baseline in lipid and apolipoprotein levels and ratios following addition ofcolesevelam hydrochloride (HCl) orplacebo to ongoing
metformin, sulfonylurea or insulin therapy.
Metformin—change at week 26 Sulfonylurea—change at week 26 Insulin—change at week 16
Colesevelam HCl Placebo Colesevelam HCl Placebo Colesevelam HCl Placebo
LS mean percent change from baseline
LDL-C −12.3a +3.7 −16.1a +0.6 −12.3a +0.5
TC −4.1a +3.1 −4.9a +0.1 −3.1 +0.5
HDL-C +1.1 +0.2 +0.5 +0.3 −0.5 +0.4
Non–HDL-C −5.6a +4.7 −6.1a +0.6 −3.2 +0.8
TGb +11.8 +6.6 +19.5a +1.0 +22.7a +0.3
Apolipoprotein A-I +4.3 +2.5 +5.9a +2.1 +4.7 +2.5
Apolipoprotein B −4.0 +3.9 −5.9a +0.8 −4.4a +0.9
LS mean change in ratio
TC/HDL-C −0.21a +0.17 −0.24a 0.00 −0.16 +0.01
LDL-C/HDL-C −0.32a +0.04 −0.44a −0.01 −0.36a −0.03
Non–HDL-C/HDL-C −0.21a +0.17 −0.24a 0.00 −0.16 +0.01
Apolipoprotein B/A-I −0.07a 0.00 −0.10a −0.01 −0.07a −0.02
HDL-C, high-density lipoprotein cholesterol; LS, least-squares; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides.
ap ≤ 0.004 vs. placebo.
bTG values reported as medians.
Figure 3. Changefrombaselinetoendpointinmedianhigh-sensitivityC-
reactiveprotein(hsCRP)levelswithadditionofcolesevelamHClcompared
with placebo, to ongoing metformin, sulfonylurea or insulin antidiabetes
therapies in patients with T2DM. N is the number of patients with values
atbothbaselineandendpoint.HCl,hydrochloride;LOCF,lastobservation
carried forward; T2DM, type 2 diabetes mellitus.
placebo. Colesevelam also reduced LDL-C and non-HDL-
C levels when added to ongoing antidiabetes therapies,
regardless of whether subjects were on ongoing monotherapy
or combination therapy regimens. Colesevelam increased
triglyceride levels; however, these increases were accompanied
by reduced LDL-C, total cholesterol, and non-HDL-C levels,
andincreasedHDL-Candinthelipoproteinratiosthattypically
denoteincreasedcardiovascularrisk.Theseresultshighlightthe
dual abilityofcolesevelam to improve both HbA1c and LDL-C
in patients with T2DM.
Safety of Colesevelam HCl in Combination
with Existing Antidiabetes Therapy
Safety is an important issue in patients with T2DM who
are often taking multiple medications to address the overall
pathology of insulin resistance. Colesevelam, unlike most new
pharmacological agents, has an established safety record and
was generally well tolerated across all three trials in patients
with T2DM. The rate of adverse events (AEs) was similar
between the colesevelam and placebo groups, and most AEs
were considered unrelated to the study medication (table 4).
Gastrointestinaldisorderswerethemostcommondrug-related
AEs experienced with colesevelam and included constipation
(occurring in 6.1–7.0% of patients) and dyspepsia (occurring
in 2.2–3.4% of patients) [26–28]. In the metformin trial, six
patients (3.8%) and two patients (1.3%) receiving colesevelam
andplaceborespectively,withdrewbecauseofdrug-relatedAEs.
In the sulfonylurea trial, 12 patients (5.2%) and four patients
(1.7%) receiving colesevelam and placebo respectively, and
ﬁve patients (3.4%) and two patients (1.4%) in the insulin
trial receiving colesevelam and placebo respectively, withdrew
because of drug-related AEs [26–28]. Most AEs were mild-
to-moderate in severity and none of the serious AEs were
considered to be drug-related.
The risk of hypoglycaemia is an important consideration
for any antidiabetes agent. In these three trials, colesevelam
did not signiﬁcantly increase the risk of hypoglycaemia when
added to existing metformin-, sulfonylurea- or insulin-based
therapy in patients with T2DM. In the metformin trial, one
patient who received colesevelam experienced a mild episode
of hypoglycaemia [26]. In the sulfonylurea trial, four patients
(2.0%)inthecolesevelamgroupandtwopatients(1.0%)inthe
placebo group developed hypoglycaemia that was considered
drug-related [27]. In the insulin trial, ﬁve patients (3.4%)
treated with colesevelam and eight patients (6.0%) treated
with placebo reported hypoglycaemia that was considered to
be drug-related [28]. Overall, most episodes of hypoglycaemia
were mild and resolved without discontinuation of treatment.
Meanchangesinsafetylaboratoryparametersandvitalsigns
were similar in the treatment groups of each trial [26–28].
Overall, colesevelam was found to be weight neutral when
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Table 4. The incidence of adverse events (AEs) following addition of colesevelam hydrochloride (HCl) or placebo to ongoing metformin, sulfonylurea
or insulin therapy.
Metformin Sulfonylurea Insulin
Colesevelam HCl Placebo Colesevelam HCl Placebo Colesevelam HCl Placebo
(N = 159) (N = 157) (N = 229) (N = 231) (N = 147) (N = 140)
All AEs, N (%) 85 (54.0) 81 (52.0) 145 (63.3) 126 (55.0) 92 (63.0) 82 (59.0)
Drug-related AEs, N (%) 29 (18.2) 14 (9.0) 47 (21.0) 21 (9.1) 24 (16.3) 13 (9.3)
Serious AEs, N (%) 8 (5.0)a 5 (3.2)a 8 (4.0)a 11 (5.0)a 11 (8.0)a 8 (6.0)a
Most common drug-related AEs (occurring in ≥2% of patients)
Constipation, n (%) 11 (7.0) 2 (1.3) 14 (6.1) 6 (3.0) 10 (6.8) 0
Dyspepsia, n (%) 5 (3.1) 5 (3.2) 5 (2.2) 1 (0.4) 5 (3.4) 0
Diarrhoea, n (%) 2 (1.3) 4 (3.0) 3 (1.3) 1 (0.4) NA NA
Flatulence, n (%) 2 (1.3) 1 (1.0) 2 (1.0) 3 (1.3) 3 (2.0) 0
Hypoglycaemia, n (%) 1 (1.0) 04 (2.0) 2 (1.0) 5 (3.4) 8 (6.0)
AEs and serious AEs occurring during the randomized phase of each trial. The randomized period was 16 weeks in the insulin trial and 26 weeks in both
the metformin and sulfonylurea trials. AEs, adverse events; NA, not applicable.
aNot drug-related.
added to existing antidiabetes treatment, which is another
important consideration for patients with T2DM.
Colesevelam can increase triglyceride levels in patients
with T2DM. Caution is therefore recommended in patients
with triglyceride levels >300 mg/dl (>3.4 mmol/l), and
colesevelam is contraindicated in patients with triglyceride
levels >500 mg/dl (>5.7 mmol/l) and in patients with
a history of hypertriglyceridaemia-induced pancreatitis [21].
Colesevelam has a high capacity for bile acid binding
with a low potential for interfering with the absorption of
other agents [34]. However, patients taking levothyroxine,
oral contraceptives or glyburide should take these agents
at least 4 h before colesevelam to avoid any potential for
impaired absorption. Use of colesevelam may also decrease the
absorption of fat-soluble vitamins including A, D and E [21].
The results of these trials are similar to those seen following
theadditionofthiazolidinedionestometforminorsulfonylurea
therapy [35]. Factors that may have inﬂuenced the efﬁcacy of
colesevelam in these trials (when compared with other agents)
include the low mean baseline HbA1c and the fact that there
was no ‘washout’ in the colesevelam studies [36]. Currently,
there are no data to show whether use of colesevelam reduces
mortality or morbidity in patients with T2DM. Colesevelam is
not approved for use in patients with type 1 diabetes and has
not been studied in combination with the currently approved
dipeptidyl peptidase-IV inhibitors sitagliptin or saxagliptin. In
addition, there are limited data on its use in patients receiving
thiazolidinediones.
Bile Acid Sequestrants: Mechanism(s) of
Action for Their Glycemic Effects
The mechanism(s) by which colesevelam lowers glucose levels
in patients with T2DM is not yet clearly understood. However,
there is increasing evidence that the glycaemic effects of bile
acid sequestrants may occur through farnesoid X receptor
(FXR/bile acid receptor), liver X receptor, ﬁbroblast growth
factor-19 and TGR5-mediated effects on intestinal glucose
absorption and/or hepatic glucose metabolism, in addition to
inﬂuences on peripheral insulin sensitivity, incretin effects and
energyhomeostasis.BileacidactivationofFXRhasbeenshown
to reduce expression of genes involved in gluconeogenesis
including phosphoenolpyruvate carboxykinase and glucose-6-
phosphatase. In addition, FXR may modulate hepatic glucose
production during fasting and postprandial hepatic glucose
utilization [37–40]. Alterations in the bile acid pool in T2DM
and its effect(s) on FXR activation are still under investigation.
Emerging data suggest a partial regulatory role for FXR
modulatorsinperipheralinsulinsensitivity,suggestingafuture
role for FXR in the treatment of insulin resistance and
T2DM [41–43]. Bile acids may also affect incretin release,
having been shown to induce secretion of glucagon-like
peptide-1 (GLP-1) through activation of the G-protein-
coupled receptor TGR5 [44,45]. The bile acid sequestrant
colestimide was shown to result in increased secretion of
GLP-1 in patients with T2DM, although the functional
consequences are unclear [46]. Bile acids have also been
implicated in metabolic regulation, through FXR-mediated
regulation of energy substrate mobilization and storage [47].
These glycaemic effects appear to be unique to bile acid
sequestrants,withinwhichonlycolesevelamhasbeenapproved
for improving glycaemic control in adults with T2DM. These
effects have not been observed with the cholesterol absorption
inhibitor ezetimibe. Despite these advances, further study is
needed to determine the precise mechanism underlying the
effectofbileacidsequestrantsonglucosemetabolisminpatients
with T2DM.
Conclusion
The additional reduction in HbA1c and LDL-C levels achieved
with the addition of colesevelam to current antidiabetes
therapies may help patients with T2DM achieve target levels
for HbA1c and LDL-C. Favourable modiﬁcation of these two
factorsplusloweringnon-HDL-Clevelsmaymakecolesevelam
ausefuladjunctivetherapytoreduceoverallcardiovascularrisk
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inpatientswithT2DM.Colesevelamiscurrentlyrecommended
for the treatment of T2DM in combination with antidiabetes
therapies such as metformin, sulfonylurea and insulin, and
has been added to the treatment roadmap developed by the
American Association of Clinical Endocrinologists [48], and
to the clinical guideline for pharmacological management of
T2DM developed by the Joslin Diabetes Center and Joslin
Clinic [49].
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